Emergent Biosolutions EBS Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | -$190.6M+74.9% | -$760.5M-259% | -$211.6M-196% | ||
| $95.8M-11.9% | $108.8M-13.0% | $125.1M-12.7% | $143.3M+15.8% | ||
| $16.2M-10.0% | $18M-22.1% | $23.1M-48.8% | $45.1M+6.4% | ||
| —— | —— | —— | -$28.6M-162% | ||
| $9.8M— | —— | $21.3M+420% | $4.1M0.0% | ||
| -$4.5M— | —— | -$21.1M-486% | -$3.6M— | ||
| -$25.5M— | —— | —— | —— | ||
| —— | —— | -$600K— | —— | ||
| —— | -$33M— | —— | —— | ||
| —— | —— | -$56.6M— | —— | ||
| —— | -$183.6M-1,469% | -$11.7M— | —— | ||
| —— | -$6.5M-180% | $8.1M— | —— | ||
| $5.2M— | —— | $5.9M-38.5% | $9.6M+130% | ||
| —— | —— | -$16.2M-156% | $28.7M+192% | ||
| $172.9M— | —— | —— | —— | ||
| $13.8M-39.7% | $22.9M-55.6% | $51.6M-55.4% | $115.8M-48.3% | ||
| —— | $7.9M— | —— | $0— | ||
| —— | $125.2M— | —— | -$381.3M-70.1% | ||
| $24.9M— | —— | $0-100% | $82.1M-22.5% | ||
| $0— | $0-100% | $8.4M— | $0— | ||
| $1.4M+16.7% | $1.2M-52.0% | $2.5M-57.6% | $5.9M-57.2% | ||
| -$136.6M+28.3% | -$190.5M+64.7% | -$540.4M-212% | $481.2M+441% | ||
| —— | $0+100% | -$1.2M-340% | $500K— | ||
| —— | -$6.1M+98.9% | -$554.8M-937% | $66.3M— | ||
| $49.7M-22.3% | $64M-6.3% | $68.3M+107% | $33M+8.6% | ||
| $40M— | —— | $52.8M— | —— | ||
| $9.8M— | —— | $21.3M+420% | $4.1M0.0% | ||
| -$4.5M+84.4% | -$28.9M— | —— | -$3.6M— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$16.2M-156% | $28.7M+192% | ||
| $3.1M-13.9% | $3.6M-25.0% | $4.8M— | $0— | ||
| —— | -$183.6M-1,469% | -$11.7M— | —— | ||
| —— | -$6.5M-180% | $8.1M— | —— | ||
| —— | -$30M-576% | $6.3M— | $0— | ||
| —— | $0— | $0— | —— | ||
| —— | $7.9M— | —— | $0— | ||
| $3.8M— | $0— | $0— | —— | ||
| $0-100% | $1.5M-16.7% | $1.8M-64.0% | $5M-68.6% | ||
| —— | —— | —— | —— | ||
| —— | $1.1M— | —— | $0— | ||
| $5.2M— | —— | $5.9M-38.5% | $9.6M+130% | ||
| $162.5M— | —— | —— | —— | ||
| $162.5M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Emergent Biosolutions generate?
- Emergent Biosolutions (EBS) generated $150.3M in operating cash flow over the trailing twelve months.
- What is Emergent Biosolutions's free cash flow?
- After $12.6M of capital expenditures, Emergent Biosolutions's free cash flow was $141.1M over the trailing twelve months, up 310.0% year over year.
- Where does Emergent Biosolutions's cash flow data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
